Phase 3 results reported for CagriSema last month were a disappointment, however, with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a ...
7h
Hosted on MSNWall Street's Most Wanted: 2 Highly Shorted Stocks Right NowShort-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results